Search

May 8, 2014 - This expert consensus statement was developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) and endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD).

May 8, 2014 - This expert consensus statement was developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) and endorsed by the governing bodies of PACES, HRS, and the American College of Cardiology (ACC). Endorsed by the American Academy of Pediatrics (AAP) (which uses a different classification of evidence).

June 26, 2012 — The statement is the first of its kind to specifically address pacemaker device and mode selection, expanding upon the ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities.

The new statement provides a state-of-the-art review of the field and reports consensus recommendations on pacemaker device and mode selection. It is a guide to facilitate the appropriate use of single vs. dual-chamber devices for patients who already meet guidelines for pacemaker implantation.

This document has been retired and replaced by the 2017 publication available at this link.

March 2012 — The purpose of the 2012 Consensus Statement is to provide a state-of-the-art review of the field of catheter and surgical ablation of AFib. It reports  on the findings of a Task Force, convened by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), and the European Cardiac Arrhythmia Society (ECAS) and charged with defining the indications, techniques, and outcomes of this procedure.

February 14, 2011 — This guideline update, states that dabigatran, a new antithrombotic agent that was recently approved by the U.S. Food and Drug Administration, is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation. The update is a joint publication of the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Heart Rhythm Society (HRS). 

This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."

This document was developed in partnership with the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology, and the Asia Pacific Heart Rhythm Society (APHRS); and in collaboration with the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the Pediatric and Congenital Electrophysiology Society (PACES) and the Association for European Pediatric and Congenital Cardiology (AEPC).

March 20, 2006 — Following the recall event in 2005, the Guidant Corporation commissioned an independent panel charged with studying, analyzing, and evaluating the policies and procedure of the Cardiac Rhythm Management (CRM) business with regard to post-market device surveillance. This report summarizes the findings and recommendations of the panel.

August 31, 2010 — A new study on overall workforce trends in the field of cardiac electrophysiology (EP) reveals an increasing demand for EP professionals resulting from shifting demographic trends, evolving health reform policies, and improved procedural outcomes. The study, commissioned in 2009 by the Heart Rhythm Society, provides data from nearly 700 respondents, including EPs, allied professionals, and basic scientists currently working within the field of cardiac electrophysiology. It found substantial growth in the overall volume and complexity of cardiac procedures performed in the past decade.